Evaluation of three lymph node staging systems for prognostic prediction in gastric cancer: A systematic review and meta-analysis

Table 1 Demographic details of all identified studies

Ref.	Year	Patient (n)	Age (Year)	Country	Racial	NLN	MLN	Follow-up time	TNM edition
Villalabeitia Ateca et al[28]	2022	199	NA	Spain	White	NA	NA	2010-2014	7th
Gu et al[29]	2021	7620	58.3 ± 11.7	China	Yellow	23.2 ± 13.1	4.9 ± 7.5	2001-2011	8th
Cao et al[30]	2019	877	NA	China	Yellow	NA	NA	2010-2012	8th
Pan et al[31]	2019	1730	56.3 ± 14.3	China	Yellow	23.8 ± 14.3	3.3 ± 6.0	1987-2012	8th
Lee et al[32]	2016	3929	56.8 ± 18.3	Korea	Yellow	41.2 ± 16.5	3.22 ± 6.8	1990-2012	7th
Calero et al[33]	2015	326	66.8 ± 15.3	Spain	White	27.5 ± 17.0	14.8 ± 13.75	2004-2010	7th
Aurello et al[19]	2014	177	63.0 ± 14.0	Italy	White	26.4 ± 12.0	6.9 ± 10.6	1997-2012	7th
Liu et al[22]	2013	372	58.9 ± 11.9	China	Yellow	23.2 ± 8.3	5.0 ± 4.7	2001-2006	7th
Sun et al[34]	2010	2517	NA	China	Yellow	21.1 ± 12.8	4.13 ± 6.63	1980-2008	6th
Koh et al[35]	2017	1243	58.5 ± 16.5	Korea	Yellow	43.5 ± 20.7	4.00 ± 8.93	2003-2013	7th
Tóth et al[36]	2017	164	64.3 ± 13.8	Hungary	White	15.0 ± 9.3	7.4 ± 5.8	2005-2010	8th
Jian-Hui et al[14]	2015	935	56.5 ± 15.8	China	Yellow	47.5 ± 35.0	33.3 ± 31.0	1994-2008	7th

NLN: Number of lymph nodes; MLN: Metastatic lymph nodes; NA: Not available; TNM: Tumor node metastasis.